)
Werewolf Therapeutics (HOWL) investor relations material
Werewolf Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Strategic review produced the pending Ambros merger, a proposed $150.0M concurrent PIPE, and sales of the JZP898 program to Jazz and platform assets to EMD; ongoing operations depend on timely merger completion.
The WTX-124 and WTX-330 Phase 1/1b and Phase 1b/2 trials were completed in Q4 2026; further development requires additional funding, and strategic partnerships are being sought.
Financial highlights
Q3 2026 net loss was $9.9M, or $0.20/share, vs. $16.4M, or $0.36/share, in Q3 2025; 9M net loss was $19.7M vs. $52.4M.
9M revenue was $21.0M from the Jazz asset sale vs. zero in 9M 2025; Q3 revenue was not listed in the operating statement.
Q3 R&D fell to $2.2M from $11.6M, while G&A rose to $7.9M from $4.1M, primarily reflecting lower trial and personnel costs and higher strategic transaction fees.
Cash and cash equivalents were $41.9M at Sept. 30, 2026 vs. $57.1M at Dec. 31, 2025; accumulated deficit was $495.1M.
Outlook and guidance
Near-term costs are expected to decline with workforce reductions, trial completions and other savings; resuming trial enrollment or preclinical work would increase R&D and G&A costs.
Existing cash is insufficient for the current operating plan through 12 months from issuance; continued operations depend on the merger or additional liquidity.
Further WTX-124 and WTX-330 development needs additional funding; expense levels and future plans depend on the merger outcome and strategic review.
- Q2 profit from $21M asset sale and debt repayment, but cash and going concern risks remain.HOWL
Q2 2026 - Restructuring, asset sale, and loan repayment narrowed losses but liquidity risks persist.HOWL
Q1 2026 - Strategic review underway with improved financials and continued progress in oncology pipeline.HOWL
Q4 2025 - Shelf registration allows up to $150M in offerings, with $12.5M at-the-market via Leerink Partners.HOWL
Registration Filing - Virtual meeting to elect directors and ratify auditor, with robust governance and compensation policies.HOWL
Proxy Filing - INDUKINE cytokine prodrugs deliver durable responses with favorable safety in advanced cancers.HOWL
7th Annual Evercore ISI HealthCONx Healthcare Conference - Durable responses and strong safety support expansion at 18mg in refractory solid tumors.HOWL
Study Update - WTX-124 and WTX-330 show strong early efficacy and safety, with pivotal data expected in late 2024.HOWL
24th Annual Needham Virtual Healthcare Conference - WTX-124 demonstrates durable responses in tough cancers, with expansion and registration plans underway.HOWL
Leerink’s Global Healthcare Conference 2025
)
)
)
)
)
)
)
)